Post-marketing studies are the new norm

Have a funny feeling that post-marketing safety studies are more and more prevalent these days? Well, it's not just a feeling. The Tufts Center for the Study of Drug Development found that drugmakers are increasingly bound to study their products after they hit the market--and not only in the U.S., but in Europe and Japan, too.

Over the last decade, in fact, 75 percent of newly approved drugs in Europe and the U.S. and 50 percent in Japan came onto the market trailing a requirement for post-approval studies. "What used to be the exception is increasingly becoming the rule," the study's author said in a statement, adding that post-marketing studies may help identify safety issues earlier and help drugmakers serve patients better.

- check out the release from Tufts
- read the Boston Globe story

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.